Morgan Stanley
DRUG

Morgan Stanley’s Bright Minds Biosciences DRUG Stock Holding History

Morgan Stanley’s Portfolio DRUG Stock Details DRUG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$9.69M Buy
132,764
+642
+0.5% +$51.7K ﹤0.01% 3591
2025
Q4 		$10.3M Sell
132,122
-60,744
-31% -$4.06M ﹤0.01% 3584
2025
Q3 		$11.7M Buy
192,866
+30,797
+19% +$1.2M ﹤0.01% 3406
2025
Q2 		$4.23M Buy
162,069
+5,519
+4% +$165K ﹤0.01% 4191
2025
Q1 		$5.65M Sell
156,550
-11,090
-7% -$406K ﹤0.01% 3824
2024
Q4 		$6.04M Buy
+167,640
New +$5.9M ﹤0.01% 3844

Other funds holding DRUG

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Morgan Stanley's DRUG Position: Q1 2026 in Review

Morgan Stanley increased its Bright Minds Biosciences (DRUG) stake by 0.49% in Q1 2026, buying an estimated $51.7K and bringing the position to 132,764 shares worth $9.69M. The position accounts for ﹤0.01% of the portfolio, ranked #3591.

Morgan Stanley first reported a position in DRUG in Q4 2024 and has held it in 6 quarters since. The position peaked at $11.7M in Q3 2025. 94 funds tracked by Wall St. Rank hold DRUG as of Q1 2026.

  • Morgan Stanley held 132,764 shares of Bright Minds Biosciences worth $9.69M as of Q1 2026.
  • Morgan Stanley bought 642 Bright Minds Biosciences shares in Q1 2026, an estimated $51.7K.
  • Bright Minds Biosciences made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #3591 holding.
  • Morgan Stanley first reported a position in Bright Minds Biosciences in Q4 2024 and has held it in 6 quarters since.
  • Morgan Stanley's Bright Minds Biosciences position peaked at $11.7M in Q3 2025.
  • 94 funds tracked by Wall St. Rank held Bright Minds Biosciences as of Q1 2026.

Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.